Recent meetings
No recorded meetings with EU commissioners.
Mission & Goals
Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.
EU Legislative Interests
Single marketing authorisation for new medicines
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
www.bio.org
Additional Information
The company has received support from the EIC accelerator for a total amount of EUR 17.5M (EUR 15M equity and EUR 2,5M subsidy). The company has recently been awarded follow-on equity support from the EIC up to EUR 30M. The company has not spent dedicated money for its relationship with the EU - indicated amount is estimate of FTEs spent on contacts with EIC.